Expertise in
11
conditions

Piotr Wiland

Chałubińskiego Street 6a, 
Wroclaw, DS, PL 
Expertise in
11
conditions
Chałubińskiego Street 6a, 
Wroclaw, DS, PL 
OverviewLocationsClinical Research

Overview

Piotr Wiland practices in Wroclaw, Poland. Mr. Wiland is highly rated in 11 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Sjogren Syndrome, and Dry Mouth.

His clinical research consists of co-authoring 119 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Chałubińskiego Street 6a, Wroclaw, DS 50368, Poland
Other Locations
26 Krakowska St, Wroclaw, DS 50425, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: December 20, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

119 Total Publications

Correction: Pulmonary arteritis in the course of granulomatosis with polyangiitis.
Correction: Pulmonary arteritis in the course of granulomatosis with polyangiitis.
Journal: Rheumatology international
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wiland's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile